Novogene Acquires an Illumina HiSeq X Ten Sequencing System

  Novogene Acquires an Illumina HiSeq X Ten Sequencing System

      First-in-China Deal Increases Novogene’s Investment in Illumina’s
                    Next-Generation Sequencing Technology

Business Wire

SAN DIEGO -- February 13, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn),
a leading genomics service provider based in Beijing, China, purchased one
HiSeq X Ten. This strategic investment expands Novogene’s capacity with
Illumina’s next-generation sequencing systems, which also includes HiSeqs and
MiSeqs.

“The HiSeq X Ten will enhance our capability for cancer genomics and for
mapping human disease genes, while enabling us to do population sequencing,”
said Dr. Ruiqiang Li, CEO of Novogene.

“We are excited Novogene is investing in the HiSeq X Ten to further accelerate
cancer and genetic disease research in China,” said Jay Flatley, CEO of
Illumina. “Novogene’s portfolio provides the power to conduct the full range
of next-generation sequencing applications from population scale sequencing,
on the HiSeq X Ten, to exomes, targeted panels and RNA applications on HiSeq
and MiSeq.”

The HiSeq X Ten  is the world’s first platform to deliver full coverage human
genomes for less than $1,000, including typical instrument depreciation, DNA
extraction, library preparation, and estimated labor. Purpose-built for
population-scale human whole genome sequencing, the HiSeq X Ten can sequence
tens of thousands of samples annually with high-quality, high-coverage
sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing
systems, each generating up to 1.8 terabases (Tb) of sequencing data in less
than three days or up to 600 gigabases (Gb) per day, per system.

AboutIllumina

Illumina(www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.